In a fresh dis­ap­point­ment, Am­gen spot­lights a ma­jor safe­ty is­sue with KRAS com­bo

Am­gen had hoped that its lat­est study match­ing its land­mark KRAS G12C drug Lumakras with check­point in­hibitors would open up its treat­ment hori­zons and ex­pand its com­mer­cial po­ten­tial. In­stead, the com­bo spurred safe­ty is­sues that blunt­ed ef­fi­ca­cy and forced the phar­ma gi­ant to al­ter course on its treat­ment strat­e­gy, once again dis­ap­point­ing an­a­lysts who have been track­ing the drug’s fal­ter­ing sales and lim­it­ed ther­a­peu­tic reach.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER